M. Henry‐Amar

15.0k total citations · 2 hit papers
205 papers, 9.7k citations indexed

About

M. Henry‐Amar is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M. Henry‐Amar has authored 205 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pathology and Forensic Medicine, 82 papers in Pulmonary and Respiratory Medicine and 62 papers in Oncology. Recurrent topics in M. Henry‐Amar's work include Lymphoma Diagnosis and Treatment (86 papers), Lung Cancer Treatments and Mutations (47 papers) and Multiple and Secondary Primary Cancers (25 papers). M. Henry‐Amar is often cited by papers focused on Lymphoma Diagnosis and Treatment (86 papers), Lung Cancer Treatments and Mutations (47 papers) and Multiple and Secondary Primary Cancers (25 papers). M. Henry‐Amar collaborates with scholars based in France, Netherlands and Belgium. M. Henry‐Amar's co-authors include A.M. Mandard, Patrice Carde, G Samama, J. Marnay, J.-C. Mandard, John Jacob, Jean François Petiot, Alexandre Roussel, Sylvie Bonvalot and P Ségol and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

M. Henry‐Amar

200 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations

1994 1.6k citations M. Henry‐Amar et al. profile →
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

1996 487 citations M. Henry‐Amar et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by M. Henry‐Amar

Since Specialization

Citations

This map shows the geographic impact of M. Henry‐Amar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Henry‐Amar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Henry‐Amar more than expected).

Fields of papers citing papers by M. Henry‐Amar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Henry‐Amar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Henry‐Amar. The network helps show where M. Henry‐Amar may publish in the future.

Co-authorship network of co-authors of M. Henry‐Amar

This figure shows the co-authorship network connecting the top 25 collaborators of M. Henry‐Amar. A scholar is included among the top collaborators of M. Henry‐Amar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Henry‐Amar. M. Henry‐Amar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment 2022 ·British Journal of Cancer ·(unknown), Carolé Rubino, Rodrigue S. Allodji, (unknown), Stéphane Bardet, Ibrahima Diallo, Massimo E. Dottorini, (unknown), Per Hall, M. Henry‐Amar, Stéphanie Lamart, (unknown), Stefan Lönn, Marcel Ricard, Claire Schvartz, Martin Schlumberger, Neige Journy, Florent de Vathaire	5
2	Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study 2009 ·Clinical Genitourinary Cancer ·Florence Joly, Nadine Houédé, Sabine Noal, Christine Chevreau, Frank Priou, P. Chinet-Charrot, Frédéric Rolland, Aude Fléchon, M. Henry‐Amar, Stéphane Culine	41
3	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials 2006 ·Journal of Clinical Oncology ·Evert M. Noordijk, Patrice Carde, N. Dupouy, Anton Hagenbeek, Augustinus D. G. Krol, Hanneke C. Kluin‐Nelemans, Umberto Tirelli, M. Monconduit, José Thomas, Houchingue Eghbali, Berthe M.P. Aleman, Jacques Bosq, Marjeta Vovk, Tom Verschueren, (unknown), T. Girinsky, John Raemaekers, M. Henry‐Amar	149
4	Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera. 2006 ·PubMed ·(unknown), O. Switsers, (unknown), Jimmy Jacob, T. Delozier, (unknown), (unknown), (unknown), M. Henry‐Amar, Stéphane Bardet	2
5	Expression of α V-associated integrin β subunits in epithelial ovarian cancer andits relation to prognosis in patients treated with platinum-based regimens 2005 ·The Histochemical Journal ·Sylvie Maubant, Séverine Cruet-Hennequart, Soizic Dutoit, Yves Denoux, H. Crouet, M. Henry‐Amar, Pascal Gauduchon	24
6	Densité minérale osseuse et marqueurs biologiques de remaniement osseux chez des patients porteurs d’incidentalome surrénalien : effet d’un hypercortisolisme infraclinique 2002 ·La Revue de Médecine Interne ·Stéphane Bardet, V. Rohmer, F Casson, Christine Coffin, (unknown), Julia Sabatier, Philippe Lecomte, Maurice Audran, M. Henry‐Amar, Antoine Tabarin	19
7	Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884 2001 ·Blood ·(unknown), Berthe M.P. Aleman, M. Henry‐Amar, Umberto Tirelli, Anton Hagenbeek, Patrice Carde, W Peters, Radka Tomšič, A Van Hoof, M. van ‘t Veer, José Thomas, (unknown), Hanneke C. Kluin‐Nelemans, Catherine Sebban, Dominique Bron, Houchingue Eghbali, A. Pinna, (unknown)	6
8	Quality of life assessment in Hodgkin’s disease: A new comprehensive approach 1998 ·Annals of Oncology ·Hans‐Henning Flechtner, Jens Ulrich Rüffer, M. Henry‐Amar, W. A. M. Mellink, M. Sieber, Christophe Fermé, Houchingue Eghbali, Andreas Josting, Volker Diehl	27
9	Maladie de Hodgkin. Les complications à long terme de la radiothérapie. 1997 ·La Presse Médicale ·J M Cosset, M. Henry‐Amar	3
10	A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis 1997 ·International Journal of Radiation OncologyBiologyPhysics ·É. Bardet, Alain Rivière, Anne Charloux, Dominique Spaëth, A Ducoloné, A. Le Groumellec, B. Pellae-Cosset, M. Henry‐Amar, Jean‐Yves Douillard	8
11	Les cancers génitaux et mammaires féminins en France : répartition géographique et estimation de l’incidence 1997 ·Bulletin du Cancer ·Gilles Chaplain, Pascale Grosclaude, P. Arveux, N Raverdy, (unknown), M. Henry‐Amar, Paul Schaffer, Jean‐Pierre Daurès, Florent de Vathaire	4
12	Nebulized Versus Intravenous Albuterol in Hypercapnic Acute Asthma. A Multicenter, Double-Blind, Randomized Study 1994 ·American Journal of Respiratory and Critical Care Medicine ·S. Salmerón, Laurent Brochard, Hervé Mal, Alain Tenaillon, M. Henry‐Amar, (unknown), P Duroux, Gérald Simonneau	70
13	Follow-up thallium-201 scintigraphy after mantle field radiotherapy for hodgkin's disease 1993 ·International Journal of Radiation OncologyBiologyPhysics ·Jean‐Yves Pierga, C. Maunoury, Héric Valette, Gèrard Socié, T. Girinski, Gil Tchernia, M. Henry‐Amar, (unknown), Jean‐Marc Cosset	19
14	The Second International Symposium on Hodgkin's Disease. Workshop I: Review on prognostic factors. 1992 ·PubMed ·Markus Löffler, Peter Mauch, KA MacLennan, Lena Specht, M. Henry‐Amar	6
15	The EORTC trials for limited stage Hodgkin's disease 1992 ·European Journal of Cancer ·Jean‐Marc Cosset, M. Henry‐Amar, J.H. Meerwaldt, Patrice Carde, Evert M. Noordijk, José Thomas, J. M. V. Burgers, R. Somers, M. Hayat, M Tubiana	47
16	Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience 1991 ·Annals of Oncology ·Jean‐Marc Cosset, M. Henry‐Amar, J.H. Meerwaldt	82
17	Specific Controversies Concerning the Natural History of Renal Disease in Pregnancy 1991 ·American Journal of Kidney Diseases ·Paul Jungers, Pascal Houillier, (unknown), M. Henry‐Amar	34
18	Postoperative pulmonary complications: general anesthesia with postoperative parenteral morphine compared with epidural analgesia. 1988 ·PubMed ·Christian Jayr, (unknown), (unknown), (unknown), J Masselot, P Lasser, A. Denjean, (unknown), M. Henry‐Amar	54
19	Chronic kidney disease and pregnancy. 1986 ·PubMed ·P Jungers, (unknown), M. Henry‐Amar, G Albouze, Philippe Fournier, Ulrich M. Vischer, (unknown), Nöel Lh, Grünfeld Jp	63
20	[Treatment of clinical stages I and II of Hodgkin's disease]. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·M Tubiana, G Mathé, Muhammad Abid Hayat, (unknown), M. Henry‐Amar, A Laugier	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact